curriculum vitae joaquín v. arribas lópez (fecha...

Curriculum Vitae

Joaquín V. Arribas López (Fecha Nacimiento: 12/12/1964)

DIRECCIÓN

Preclinical Research Program

Vall d’Hebron Institut d'Oncologia (VHIO)

Pssg. Vall d’Hebron 119-129

Barcelona 08035

Tel.: +34 93 274 6026

Fax: +34 93 489 3884

e-mail: [email protected]

EDUCACIÓN

1987 Licenciatura en Biología (Bioquímica y Biología Molecular). Universidad Autónoma de Madrid

1992 PhD Docotorado en Ciencias (Biologia). Universidad Autónoma de Madrid

POSICIÓN ACTUAL

2007- actualidad. ICREA Research Professor. Institució Catalana de Recerca i Estudis Avançats (ICREA).

(http://www.icrea.es/).

2011- actualidad Director Programa de Investigación Preclinica, Vall d’Hebron Institut d’Oncologia (VHIO)

2009- actualidad Profesor Asociado , Departmento de Bioquimica y Biologia Molecular, Universitat Autónoma de

Barcelona (UAB).

EXPERIENCIA PROFESIONAL Y ACADEMICA 1988-1992 Predoctoral Fellow, Ministerio de Educación y Ciencia. Facultad de Medicina, UAM

Jun-Oct 1990 Predoctoral Fellow, National Cancer Institute. Frederick Cancer Research Facility

1993-1997 Postdoctoral fellow. Ministerio de Educación y Ciencia. Memorial Sloan-Kettering Cancer Center.

1997-2006 Faculty, Institut Catalá de la Salut (ICS). Hospital Universitario Vall d’Hebron

mailto:[email protected]

http://www.icrea.es/

2

Publicaciones

García-Parra, J., Arpí, O., Morancho, B., Dalmases, A., Menendez, S., Zazo, S., Chamizo

, C., Eroles, P.,

Servitja, S., Tusquets, I., Yelamos, J., Lluch, A., Arribas, J., Rojo, F., Rovira, A. and Albanell, J. Poly

(ADP-ribose) polymerase inhibition enhances trastuzumab antitumor activity in HER2 overexpressing

breast cancer (2012) Submitted.

Serra, V., Eichhorn, P. J. A., Celina García-García, C., Ibrahim, Y. I., Prudkin, P., Sánchez, G., Rodríguez,

O., Antón, P., Parra, J. Ll., Marlow, S., Scaltriti, M., Aleix Prat4, Arribas, J., Hahn, W. C., Kim, S. Y. and

Baselga, J. (2013) RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest, in

press.

Pedersen, K., Canals, F., Tabernero, J. and Arribas, J. (2012) PELO negatively regulates HER-receptor

signalling and metastasis (2013) Oncogene 2012, Feb 25 doi: 10.1038/onc.2013.35. [Epub ahead of print].

(http://www.nature.com/onc/journal/vaop/ncurrent/full/onc201335a.html).

Angelini, P. D., Zacarias-Fluck, M. F., Parra-Palau, J. Ll., Guiu, M., Pedersen, K., Bernadó Morales, C.,

Luque-García, A., Peiró Novalpotro, N., Giralt, J., Canals, F., Villanueva, J., Gomis, R. R., Baselga, J. and

Arribas, J. (2013) Constitutive HER2 signaling promotes breast cancer metastasis through cellular

senescence. Cancer Res, 73, 450-458. (http://cancerres.aacrjournals.org/content/73/1/450.abstract)

Morancho, B., Parra-Palau, J. Ll., Ibrahim, Y. H., Bernadó Morales, C., Bech-Serra, J. J., Pandiella, A.,

Canals, F., Baselga, J. and Arribas, J. (2013) A dominant negative N-terminal fragment of HER2

frequently expressed in breast cancers. Oncogene 32, 1452-1459.

(http://www.nature.com/onc/journal/v32/n11/full/onc2012152a.html) Epub 2012 May 28.

Koziol, A., Gonzalo, P., Mota, A., Pollán, A., Lorenzo, C., Colomé, N., Montaner, D., Dopazo, J., Arribas,

J., Canals, F., Arroyo, A. G. (2012) The protease MT1-MMP drives a combinatorial proteolytic program in

activated endothelial cells. FASEB J 26, 4481-4494. (http://www.fasebj.org/content/26/11/4481.abstract)

Esteve, P., Sandonìs, A., Cardozo, M., Malapeira, J., Ibañez,

C., Crespo, I., Gonzalez-Garcia,

S., Marcos,

S., Torribio, M. L., Arribas, J., Shimono, A., Guerrero, I. and Bovolenta, P. (2011) Secreted Frizzled-

Related Proteins act as negative modulators of ADAM10 metalloproteinase activity during retinal

neurogenesis. Nat Neurosci 14, 562-569. http://www.nature.com/neuro/journal/v14/n5/full/nn.2794.html.

Article recommended by Faculty of 1000 (http://f1000.com/11005956#evaluations)

Arribas, J., Baselga, J., Pedersen, K. and Parra-Palau, J. Ll. (2011) p95HER2 and breast cancer. Cancer

Res 71, 1515-1519. http://cancerres.aacrjournals.org/content/71/5/1515.abstract

Serra, V., Scaltriti, M., Prudkin, L., Eichhorn, P., Ibrahim, Y. H., Chandarlapaty, S., Markman, B.,

Rodriguez, O., Guzman, M., Rodriguez, S., Gili, M., Russillo, M., Parra, J. Ll., Singh, S., Arribas, J.,

Rosen, N., and Baselga, J. (2011) PI3K inhibition results in enhanced HER signaling and acquired ERK

dependency in HER2 overexpressing breast cancer. Oncogene 30, 2547-2557.

http://www.nature.com/onc/journal/vaop/ncurrent/full/onc201335a.html

http://cancerres.aacrjournals.org/content/73/1/450.abstract

http://www.nature.com/onc/journal/v32/n11/full/onc2012152a.html

http://www.fasebj.org/content/26/11/4481.abstract

http://www.nature.com/neuro/journal/v14/n5/full/nn.2794.html

http://f1000.com/11005956#evaluations

http://cancerres.aacrjournals.org/content/71/5/1515.abstract

3

Malapeira, J., Esselens, C., Bech-Serra, J. J. Canals, F., Arribas J. (2011) ADAM17 (TACE) regulates

TGFbeta signaling through the cleavage of vasorin. Oncogene 30, 1912-1922.


Parra-Palau, J. Ll., Pedersen, K., Peg, V., Scaltriti, M., Angelini, P. D., Escorihuela, M., Mancilla, S.,

Sánchez-Pla, A., Ramón y Cajal, S., Baselga, J., Arribas, J. (2010) A major role of p95/611-CTF, a

carboxy-terminal fragment of HER2, in the downmodulation of the ER in HER2-positive breast cancers.

Can Res 70, 8537-8546. http://cancerres.aacrjournals.org/content/70/21/8537.

Arribas, J., Parra-Palau, J. L., Pedersen, K. (2010) HER2 fragmentation and breast cancer stratification.

Clin Can Res 16, 4071-4073. http://clincancerres.aacrjournals.org/content/16/16/4071.

Scaltriti, M., Chandarlapaty, S., Prudkin, L., Aura, C., Jimenez, J., Angelini, P. D., Sánchez, G., Guzman,

M., Parra, J. L., Ellis, C., Gagnon, R., Koehler, M., Gomez, H., Geyer, C., Cameron, D., Arribas, J.,

Rosen, N. and Baselga J. (2010) Clinical Benefit of lapatinib-based therapy in patients with human

epidermal growth factor receptor-2-positive breast tumors coexpressing the truncated p95HER2 receptor.

Clin Cancer Res 16, 2688-2695. http://clincancerres.aacrjournals.org/content/16/9/2688.

Esselens, C., Malapeira, J., Colome, N., Casal, C., Rodriguez-Manzaneque, J. C., Canals, F. and Arribas,

J. (2010) The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration. J Biol Chem 285,

2463-2473. http://www.jbc.org/content/285/4/2463.abstract.

Chandarlapaty, S., Scaltriti, M., Angelini, P., Ye, Q., Guzman, M., Hudis, C. A., Norton, L., Solit, D. B.,

Arribas, J., Baselga, J. and Rosen, N. (2010) Inhibitors of HSP90 block p95-HER2 signaling in

Trastuzumab-resistant tumors and suppress their growth. Oncogene 29, 325-334.

http://www.nature.com/onc/journal/v29/n3/abs/onc2009337a.html. “Featured Original Article” of the issue

Pedersen, K., Angelini, P.-D., Laos, L., Bach-Faig, A., Cunningham, M.-P., Ferrer-Ramón, C., Luque-

García, A., García-Castillo, J., Parra-Palau, J.-Ll., Scaltriti, M., Ramón y Cajal, S., Baselga J. and Arribas,

J. (2009) A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth

and Metastasis. Mol Cell Biol 29, 3319-3331. http://mcb.asm.org/cgi/content/full/29/12/3319. Article

Recommended by Faculty of 1000 (http://f1000biology.com/article/id/1163335/evaluation)

García-Castillo, J., Pedersen, K., Angelini, P. D., Bech-Serra, J. J., Colome, N., Cunningham, M. P., Parra

Palau, J. Ll., Canals, F., Baselga, J. and Arribas, J. (2009) HER2 carboxy terminal fragments regulate cell

migration and cortactin phosphorylation. J Biol Chem 284, 25302-25313.

http://www.jbc.org/cgi/reprint/M109.001982

Arribas, J. and Esselens, C. (2009) ADAM17 as a Therapeutic Target in Multiple Diseases. Curr Pharm

Des 15, 2319-2335. http://www.bentham.org/cpd/contabs/cpd15-20

Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J., Valero, V., Guzman, M., Botero, M. L., Llonch, E.,

Atzori, F., Di Cosimo, S., Maira, M., Garcia-Echeverria, C., Parra, J. Ll., Arribas, J. and Baselga, J. (2008)

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells

with activating PI3K mutations. Cancer Res. 68:8022-8030.

(http://cancerres.aacrjournals.org/cgi/content/full/68/19/8022)

Vilar, E., Scaltriti, M., Balmana, J., Saura, C., Guzman, M., Arribas, J., Baselga, J. and Tabernero J.

(2008) Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to


http://cancerres.aacrjournals.org/content/70/21/8537

http://clincancerres.aacrjournals.org/content/16/16/4071

http://clincancerres.aacrjournals.org/content/16/9/2688

http://www.jbc.org/content/285/4/2463.abstract

http://www.nature.com/onc/journal/v29/n3/abs/onc2009337a.html

http://mcb.asm.org/cgi/content/full/29/12/3319

http://f1000biology.com/article/id/1163335/evaluation

http://www.jbc.org/cgi/reprint/M109.001982

http://www.bentham.org/cpd/contabs/cpd15-20

http://cancerres.aacrjournals.org/cgi/content/full/68/19/8022

4

irinotecan in human colorectal cancer cell lines. Br J Cancer. 99,1607-1612.

(http://www.nature.com/bjc/journal/v99/n10/abs/6604691a.html)

Scaltriti, M., Verma, C., Guzman, M., Jimenez, J., Parra, J. Ll., Pedersen, K., Smith, D. J., Landolfi, S.,

Ramon y Cajal, S., Arribas, J. and Baselga, J. (2009). Lapatinib, a HER2 tyrosine kinase inhibitor, induces

stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.

Oncogene 86, 803-814. (http://www.nature.com/onc/journal/vaop/ncurrent/abs/onc2008432a.html

Scaltriti, M., Rojo , F., Ocaña, A., Anido

, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X.,

Ramon y Cajal, S., Arribas, J., & Baselga, J. (2007) p95HER2, a truncated form of the HER2 receptor,

and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 99, 628-638.

(http://jnci.oxfordjournals.org/cgi/content/full/99/8/628)

Esselens, C. W., Malapeira, J., Colome, N., Moss, M., Canals, F. and Arribas, J. (2008) Metastasis-

associated C4.4A, a GPI-anchored protein cleaved by ADAM10 and ADAM17. Biol Chem. 389, 1075-1084.

(http://www.ncbi.nlm.nih.gov/pubmed/18979631?dopt=Citation)

Santiago-Josefat, B., Esselens, C., Bech-Serra, J. J. and Arribas, J. (2007) Post-transcriptional

upregulation of ADAM17 upon EGFR activation and in breast tumors. J Biol Chem 282, 8325-8331.

(http://www.jbc.org/cgi/content/full/282/11/8325) Article Recommended by Faculty of 1000

(http://www.f1000biology.com/article/id/1071114/evaluation)

Arribas, J., Bech Serra, J. J. and Santiago Josefat, B. (2006) ADAMs, cell migration and cancer Cancer

Met Rev. 25, 57-68. (http://www.springerlink.com/content/r4678440p1163673)

Bech Serra, J. J., Santiago Josefat, B., Esselens C., Saftig, P., Baselga, J. Arribas, J.* and Canals, F.

(2006) Proteomic Identification of Desmoglein-2 and ALCAM as substrates of ADAM17 and ADAM10 by

Difference Gel Electrophoresis. Mol Cell Biol 26, 5086-5095 (* Corresponding autor).

(http://mcb.asm.org/cgi/content/full/26/13/5086)

Zatovicova, M., Sedlakova, O., Svastova, E., Ohradanova, A., Ciampor, , F., Arribas, J., Pastorek, J. and

Pastorekova, S. (2005) Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a

metalloprotease-dependent process regulated by TACE/ADAM17 B J Cancer 93, 1267-1276.3

Anido, J., Scaltriti, M., Bech Serra, J. J., Federico Rojo, F. Baselga, J. and Arribas, J. (2006) Biosynthesis

of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J. 25, 3234-3244.

(http://www.nature.com/emboj/journal/v25/n13/abs/7601191a.html)

Arribas J. and Baselga, J. (2005) Who will benefit from anti-EGFR therapy (2005) Lancet Oncol 6, 257-

258. (http://www.sciencedirect.com)

Arribas J. (2005) Matrix metalloproteases and tumor invasion. New Eng J Med. 352, 2020-2021.

(http://content.nejm.org/cgi/content/extract/352/19/2020)

Martínez-Arca, S., Hurtando-Küttner, M., Borroto, A., and Arribas, J. (2005) Recycling of cell surface

proTGF-alpha regulates EGFR activation. J Biol Chem 280, 36970-3697.

(http://www.jbc.org/cgi/content/full/280/44/36970)

Arribas, J. and Ruiz-Paz, S. (2005) Regulation of ectodomain shedding. The ADAM Family of

Metalloproteases. Edited by Hopper and Lendeckel. Kluwer plenum

http://www.nature.com/bjc/journal/v99/n10/abs/6604691a.html

http://www.nature.com/onc/journal/vaop/ncurrent/abs/onc2008432a.html

http://jnci.oxfordjournals.org/cgi/content/full/99/8/628

http://www.ncbi.nlm.nih.gov/pubmed/18979631?dopt=Citation

http://www.jbc.org/cgi/content/full/282/11/8325

http://www.f1000biology.com/article/id/1071114/evaluation

http://www.springerlink.com/content/r4678440p1163673

http://mcb.asm.org/cgi/content/full/26/13/5086

http://www.nature.com/emboj/journal/v25/n13/abs/7601191a.html

http://www.sciencedirect.com/

http://content.nejm.org/cgi/content/extract/352/19/2020


5

1997 Baselga, J. and Arribas, J. (2004) Treating cancer’s kinase “addiciton”. Nat Med 10, 786-787.

(http://www.nature.com/cgi-taf/DynaPage.taf?file=/nm/journal/v10/n8/abs/nm0804-

786.html&dynoptions=doi1092047177).

Juanes, P. P., Ferreira, L., Montero, J. C., Arribas, J. and Pandiella. A. (2005) N-terminal cleavage of

proTGF occurs at the cell surface by a TACE-independent activity. Biochem. J 389, 161-172.

(http://www.biochemj.org/bj/389/0161/bj3890161.htm)

Helmke, B. M., Polychronidis, M., Benner, A., Thome, M., Arribas, J. and Deichmann, M. (2004)

“Melanoma metastasis is associated with enhanced expression of the syntenin gene” Oncol Rep 12, 221-

228. (http://147.52.72.117/OR/2004/volume12/number2/221.pdf)

Matar, P., Rojo, F., Cassia, R., Moreno-Bueno, G., Di Cosimo, S., Guzman, M., Rodriguez, S., Arribas, J.,

Palacios, J., Baselga, J. (2004) Combined epidermal growth factor receptor (EGFR) targeting with the

tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225):

Superiority over single-agent receptor targeting. Clin Cancer Res 9, 1274-1283

(http://clincancerres.aacrjournals.org/cgi/content/full/9/4/127)

Villanueva de la Torre, T., Bech-Serra, J. J., Ruiz-Paz, S., Baselga, J., Arribas, J. (2004) Inactivating

mutations block the Tumor Necrosis Factor-Alpha Converting Enzyme in the early secretory pathway

Biochem Biophys Res Commun 314, 1028-1035. (http://www.sciencedirect.com)

Velasco-Loyden, G., Arribas, J., López-Casillas, F. (2004) The shedding of Betaglycan is regulated by

pervanadate and inhibited by TIMP-2. J Biol Chem 279, 7721 - 773


Borroto, A., Ruíz-Paz, S., Borrell-Pagès, M., Villanueva de la Torre, T., Merlos-Suárez, A., Blobel, C. P.,

Baselga, J., and Arribas, J. (2003). A specific mechanism mediates the intracellular trafficking and

activation of TACE. J Biol Chem. 278, 25932-25939. (http://www.jbc.org/cgi/reprint/M301673200v1)

Anido, J., Matar, P., Albanell, J., Guzman, M., Rojo, F., Arribas, J., Averbuch, S. & Baselga, J. (2003).

ZD1839 (Gefitnib), a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces

the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in

HER2 overexpressing breast cancer cells. Clin Cancer Res 9, 1274-83.

(http://clincancerres.aacrjournals.org/cgi/content/full/9/4/1274)

Borrell-Pagès, M., Rojo, F., Albanell, J., Baselga, J., and Arribas, J. (2003) TACE is required for the

activation of the EGFR by TGF-alpha in tumors, EMBO J 22, 1114-1124.

(http://emboj.oupjournals.org/cgi/content/full/22/5/1114) Article classified as “Must Read” by Faculty of

1000 (http://www.f1000biology.com/article/id/1012467/evaluation)

Arribas, J. & Merlos-Suarez, A. (2003). Shedding of plasma membrane proteins. Curr Top Dev Biol

54,125-144.

Arribas, J. & Borroto, A. (2002). Protein Ectodomain Shedding. Chem Rev 102, 4627-4638.

(http://pubs3.acs.org/acs/journals/doilookup?in_doi=10.1021/cr010202t)

Mayo, I., Arribas, J., Villoslada, P., Alvarez DoForno, R., Rodriguez-Vilarino, S., Montalban, X., de

Sagarra, M. R., and Castano, J. G. (2002). The proteasome is a major autoantigen in multiple sclerosis.

Brain 125, 2658-2667. (http://brain.oupjournals.org/cgi/content/abstract/125/12/2658)

http://www.nature.com/cgi-taf/DynaPage.taf?file=/nm/journal/v10/n8/abs/nm0804-786.html&dynoptions=doi1092047177

http://www.nature.com/cgi-taf/DynaPage.taf?file=/nm/journal/v10/n8/abs/nm0804-786.html&dynoptions=doi1092047177

http://www.biochemj.org/bj/389/0161/bj3890161.htm

http://147.52.72.117/OR/2004/volume12/number2/221.pdf

http://clincancerres.aacrjournals.org/cgi/content/full/9/4/127

http://www.sciencedirect.com/


http://www.jbc.org/cgi/reprint/M301673200v1

http://clincancerres.aacrjournals.org/cgi/content/full/9/4/1274

http://emboj.oupjournals.org/cgi/content/full/22/5/1114

http://www.f1000biology.com/article/id/1012467/evaluation

http://pubs3.acs.org/acs/journals/doilookup?in_doi=10.1021/cr010202t

http://brain.oupjournals.org/cgi/content/abstract/125/12/2658

6

Baselga, J., Albanell, J., Molina, M., and Arribas, J. (2001). Mechanism of action of trastuzumab and

scientific update. Semin Oncol 28, 4-11.

Merlos-Suarez, A., Ruiz-Paz, S., Baselga, J., and Arribas, J. (2001). Metalloprotease-dependent

Protransforming Growth Factor-alpha Ectodomain Shedding in the Absence of Tumor Necrosis Factor-

alpha -converting Enzyme. J Biol Chem. 276, 48510-48517.


Molina, M. A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., and Baselga, J. (2001). Trastuzumab

(Herceptin), a Humanized Anti-HER2 Receptor Monoclonal Antibody, Inhibits Basal and Activated HER2

Ectodomain Cleavage in Breast Cancer Cells. Cancer Res 61, 4744-4749.

(http://cancerres.aacrjournals.org/cgi/content/full/61/12/4744

Velasco, G., Cal, S., Merlos-Suarez, A., Ferrando, A. A., Alvarez, S., Nakano, A., Arribas, J., and Lopez-

Otin, C. (2000). Human MT6-Matrix Metalloproteinase: Identification, Progelatinase A Activation, and

Expression in Brain Tumors. Cancer Res 60, 877-882.


Rodriguez-Vilarino, S., Arribas, J., Arizti, P., and Castano, J. G. (2000). Proteolytic Processing and

Assembly of the C5 Subunit into the Proteasome Complex. J Biol Chem 275, 6592-6599.


Jesús M. Ureña, J. M., and Arribas, J. (2000). El transporte intracelular de proteínas. El caso del TGF-

alfa. Ciencia al Dia Internacional 3, 1-14.

(http://www.ciencia.cl/CienciaAlDia/volumen3/numero1/articulos/articulo2.html)

Borrell-Pages, M., Fernandez-Larrea, J., Borroto, A., Rojo, F., Baselga, J., and Arribas, J. (2000). The

Carboxy-terminal Cysteine of the Tetraspanin L6 Antigen Is Required for Its Interaction with SITAC, a

Novel PDZ Protein. Mol Biol Cell 11, 4217-4225. (http://www.molbiolcell.org/cgi/content/full/11/12/4217)

Roghani, M., Becherer, J. D., Moss, M. L., Atherton, R. E., Erdjument-Bromage, H., Arribas, J., Blackburn,

R. K., Weskamp, G., Tempst, P., and Blobel, C. P. (1999). Metalloprotease-Disintegrin MDC9: Intracellular

Maturation and Catalytic Activity. J Biol Chem. 274, 3531-3540.


Urena, J., Merlos-Suarez, A., Baselga, J., and Arribas, J. (1999). The cytoplasmic carboxy-terminal amino

acid determines the subcellular localization of proTGF-(alpha) and membrane type matrix metalloprotease

(MT1-MMP). J Cell Sci 112, 773-784. (http://www.biologist.com/JCS/112/06/jcs98333.html)

Fernández-Larrea, J., Merlos-Suárez, A., Ureña, J. M., Baselga, J., and Arribas, J. (1999). A Role for a

PDZ Protein in the Early Secretory Pathway for the Targeting of proTGF-a to the Cell Surface. Mol Cell 3,

423-433. (http://www.molecule.org/cgi/content/abstract/3/4/423)

Merlos-Suarez, A., and Arribas, J. (1999). Mechanisms controlling the shedding of transmembrane

molecules. Biochem Soc Trans 27, 243-246.

Codony-Servat, J., Albanell, J., Lopez-Talavera, J. C., Arribas, J., and Baselga, J. (1999). Cleavage of the

HER2 Ectodomain Is a Pervanadate-activable Process That Is Inhibited by the Tissue Inhibitor of

Metalloproteases-1 in Breast Cancer Cells. Cancer Res 59, 1196-1201.






http://www.ciencia.cl/CienciaAlDia/volumen3/numero1/articulos/articulo2.html

http://www.molbiolcell.org/cgi/content/full/11/12/4217


http://www.biologist.com/JCS/112/06/jcs98333.html

http://www.molecule.org/cgi/content/abstract/3/4/423


7

Merlos-Suarez, A., Fernandez-Larrea, J., Reddy, P., Baselga, J., and Arribas, J. (1998). Pro-Tumor

Necrosis Factor-alpha Processing Activity Is Tightly Controlled by a Component That Does Not Affect

Notch Processing. J Biol Chem. 273, 24955-24962. (http://www.jbc.org/cgi/content/full/273/38/24955)

Arribas, J., Lopez-Casillas, F., and Massague, J. (1997). Role of the Juxtamembrane Domains of the

Transforming Growth Factor-alpha Precursor and the beta -Amyloid Precursor Protein in Regulated

Ectodomain Shedding. J Biol Chem. 272, 17160-17165. (http://www.jbc.org/cgi/content/full/272/27/17160)

Arribas, J., Coodly, L., Vollmer, P., Kishimoto, T. K., Rose-John, S., and Massagué, J. (1996). Diverse

Cell Surface Protein Ectodomains Are Shed by a System Sensitive to Metalloprotease Inhibitors. J Biol

Chem. 271, 11376-11382. (http://www.jbc.org/cgi/content/full/271/19/11376)

Castano, J. G., Mahillo, E., Arizti, P., and Arribas, J. (1996). Phosphorylation of C8 and C9 subunits of the

multicatalytic proteinase by casein kinase II and identification of the C8 phosphorylation sites by direct

mutagenesis. Biochemistry 35, 3782-3789.

Arribas, J., and Massague, J. (1995). Transforming growth factor-alpha and beta-amyloid precursor

protein share a secretory mechanism. J Cell Biol. 128, 433-441. (http://www.jcb.org/cgi/reprint/128/3/433)

Arribas, J., Arizti, P., and Castano, J. (1994). Antibodies against the C2 COOH-terminal region

discriminate the active and latent forms of the multicatalytic proteinase complex. J Biol Chem. 269, 12858-

12864.

Ruiz de Mena, I., Mahillo, E., Arribas, J., and Castano, J. G. (1993). Kinetic mechanism of activation by

cardiolipin (diphosphatidylglycerol) of the rat liver multicatalytic proteinase. Biochem J 296, 93-97.

Arribas, J., and Castano, J. (1993). A comparative study of the chymotrypsin-like activity of the rat liver

multicatalytic proteinase and the ClpP from Escherichia coli. J Biol Chem. 268, 21165-21171.

Arizti, P., Arribas, J., and Castano, J. G. (1993). Modulation of the multicatalytic proteinase complex by

lipids, interconversion and proteolytic processing. Enzyme Protein 47, 285-295.

Arribas, J., Luz Rodriguez, M., Alvarez-Do Forno, R., and Castano, J. (1991). Autoantibodies against the

multicatalytic proteinase in patients with systemic lupus erythematosus. J Exp. Med. 173, 423-427.

Arribas, J., and Castano, J. (1990). Kinetic studies of the differential effect of detergents on the peptidase

activities of the multicatalytic proteinase from rat liver. J Biol Chem. 265, 13969-13973.

Patentes

Patent 1




http://www.jcb.org/cgi/reprint/128/3/433

8

Tittle: METHOD FOR DIAGNOSING CANCERS EXPRESSING THE HER2 RECEPTOR OR ITS TRUNCATED VARIANTS

Inventors (by order of signature): Joaquim Arribas; Kim Pedersen; Davide Angellini; Josep Lluis Parra; Sirle Laos; Josep Baselga

Request Nr: P200801652

Priority Country: Spain

Priority Date: 02/06/2008

Entity: Institut de Recerca Hospital Universitari Vall d’Hebron; Fundació Privada Institut d’Investigació Òncologia de Vall d’Hebron; Institució Catalana de Recerca i Estudis Avançats

Extended Countries: Australia, Brasil, Canada, Suïssa, China, Eurasia, Europa, Hong Kong, Israel, India, Japó, Mèxic, Singapur, Estats Units d’Amèrica, Uruguai, Veneçuela, Sud-àfrica.

Companies exploiting it: GlaxoSmithKline

Patent 2

Tittle: ANTIBODIES AGAINST HER2 TRUNCATED VARIANT CTF-611

Inventors (by order of signature): Joaquim Arribas; Kim Pedersen; Davide Angellini; Josep Lluis Parra; Josep Baselga

Request Nr: EP 09380183,5

Priority Country: Europe


Entity: Fundació Privada Institució Catalana de Recerca i Estudis Avançats; Fundació Privada Institut d’Investigació Oncològica de Vall d’Hebron

Extended Countries: Europa, Estats Units d’Amèrica, Japó

Companies exploiting it: GlaxoSmithKline

Patente 3

Tittle: METODO DE DIAGNOSTICO DE LA ENFERMEDAD DE ALZHEIMER QUE EMPLEA SFRP1 COMO BIOMARCADOR

Inventors (by order of signature): Paola Bovolenta, Pilar Esteve, Africa Sandonis, Inmaculada Crespo, Mª Isabel Guerrero, Carmen Ibáñez, Jordi Malapeira, Joaquin Arribas, Shimono Akihiko

Request Nr: P201130560

Priority Country: Spain


Entity: Consejo Superior de Investigaciones Científicas; Vall d’Hebron Institut de Recerca; Vall d’Hebron Institute of Oncology; Institució Catalana de Recerca i Estudis Avançats; National University of Singapore

Extended Countries: None

Companies exploiting it: None

Patente 4

Tittle: MT1-MMP SUBSTRATES AS BIOMARKERS OF INFLAMMATORY ANGIOGENESIS

Inventors (by order of signature): Alicia Gárcia, Agniezka Koziol, Francesc Canals, Nuria Colome, Joaquín Arribas

Request Nr: EP 11382255,5

Priority Country: Europe


Entity: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III; Institució Catalana de Recerca i Estudis Avançats; Institut de Recerca Hospital Universitari Vall d’Hebron; Fundació Privada Institut d’Investigació Oncològica de Vall d’Hebron

Extended Countries: PCT application

Companies exploiting it: None

9

Seleccción de Conferencias (entre más de 100 comunicaciones):

Charla “Immunotherapy against breast cancer” en el Congreso “Cancer Immunotherapy” in Societat

Catalana d’Immunologia (SCI). Noviembre 2012

Participación en la tertulia sobre el cancer de mama del programa “Para todos la 2” de RTVE. Octubre

2012

Seminario “HER2 overexpression cellular senescence and metastasis in Breast Cancer. Centro de

Investigación Cooperativa (CiC) Biogune (Bilbao), Octubre 2012.

IMRA Conference (International Medical Research Association). Kobe (Japan) Junio 2012

Universidad del País Vasco XXXI Cursos del verano en San Sebastián – XXIV Cursos Europeos. Investigación e

Innovación en el ámbito Biosanitario. Participación en Mesa redonda. “Experiencia en el Vall d’Hebrón y en la

RTICC”. Julio 2012

Conferences cicle “Desafiaments del Segle XXI, IV, la veu de la Medicina, I” at Residencia d’Investigadors. May,

2012. Title: “Hacia la personalización en el cancer de mama”

Master de Oncología Molecular: Bases moleculares del cáncer. VIII edición 2012-2014. Clase impartida:

“Oncogenes que codifican factores de crecimiento y receptores tirosina-quinasa” Centro Nacional de

Investgaciones Oncológicas (CNIO) Abril 2012. (TRADUCIR!!)

Seminario en Biotech Research and Innovation Centre (BRIC), Copenhague (Dinamarca). Título charla: “HER-2

induced cellular senescence and breast cancer metastasis. Marzo 2012.

International Symposioum on Intracellular Proteosisys and Cancer (EMBO). Valencia. Title: “Cell Signaling through

protein ectodomain shedding”. November 2011

CNIO . Programa de Patología Molecular. Seminar: Title: “HER2 hyperactivation in breast cancer, from senescente

to metastasis” September 2011

Friederich Miescher Institute for Biomedical Research. Title: Series “Growth control and cancer” seminar: April,

12th 2011

IMRA Conference (International Medical Research Association). Title: “Towards personalizad cancer medicine. Breast Cancer Patients Stratification” February 17th -18th 2011 CNIO Frontiers Meeting: “Breast Cancer”. Title: “Hyperactivation of HER2 and anti-HER2 therapies” February 7th-9th 2011 Towards Personalized Cancer Medicine Conference. Title: “A major Role of 611-CTF, a Carboxy-Terminal

Fragment of HER2, in the Downmodulation of ER in HER2- Positive Breast Cancers” May, 20th 2010.

Kiel University, Medical Faculty. Title: “Specifity and Pathophysiology of Signal Transduction Pathways”

November 26th, 2009.

CNIO Seminar. Title: “The EGFR receptor pathway in breast cancer progression and treatment” Madrid, October,

1st 2009.

5th General Meeting of the International Proteolysis Society. Title: “Proteomic identification and

characterization of ADAM substrates” Patras, Greece, October, 22th 2007.

10

Gordon Research Conference on Matrix Matrix Metalloprotease. Title: “Identification and characterization of novel

ADAM and ADAMTS substrates”. Il Ciocco, Italy, June 5th 2007.

Metzincin Metalloproteases in Health and Diseases. Title: “Proteomic identification and characterization of ADAM

substrates”. Ascona, Switzerland, September 25th, 2006.

3rd

Annual Symposium on Anti-Signaling Strategies in Human Neoplasia. Title: “Characterization of a novel

product of the oncogene ErbB2”, Barcelona, September 16th, 2004 (Chairman of the session).

Gordon Research Conference on Matrix Metalloproteases. Title: "Role of TACE in EGFR-Ligand Activation and

Tumor Development", Big Sky, MT, USA, Agust 20th 2003.

Inaugural Conference, XII National Congress on Bioenergetics and Biomembranes. Title: "Biosynthesis and

shedding of proTGF-a, a prototypical ligand of the Epidermal Growth Factor Receptor", Querétaro, Mexico,

November 18th 2001.

Plenary Lecture, 26th European Peptide Symposium. Títle: "Role of protein ectodomain shedding in biological

functions", Montpellier, France, September 13th 2000.

11th UK Adhesion Meeting. Title: "Protein ectodomain shedding in the absence of TACE", London, UK,

September 5th 2000. (Chairman of the session).

Gordon Research Conference on Matrix Metalloproteases. Title: “PDZ proteins and intracellular trafficking”,

New London, New Hampshire, USA, Agust 9th 1999.

Biochemical Society Meeting, Symposium on Membrane Protein Secretases. Title: "Mechanisms controlling the

shedding of transmembrane molecules", Leicester, U.K., September 27th1998.

Gordon Research Conference on Angiotensin. Title: “A common mechanism governing the shedding of

transmembrane proteins”, Il Ciocco, Italy, April 22nd 1997.

PROYECTOS

Terapias contra tumores de mama positivos para p95HER2 y senescencia celular inducida por p95HER2

Referencia: PI1202536

Instituto de Salud Carlos III


Importe: 510.620 euros

Enero 2013-Diciembre 2015

Equipo investigador: Beatriz Morancho Armisen, Cristina Bernadó Morales, Kim Pedersen, Josep Lluis Parra

Palau, Pier Davide Angelini, Mariano Zacarias Fluck, Marta Escorihuela

Red Temática de Investigación Cooperativa

Referencia: RD12/0036/0042

Instituto de Salud Carlos III (Subdirección General de Redes y Centros de Investigación Cooperativa)


11


Equipo investigador: Beatriz Morancho Armisen, Octavio Cordoba Cardona, Josep Lluis Parra Palau, Pier Davide

Angelini, Roberto Rodriguez Revuelto, Isabel Teresa Rubio Rodriguez, Mariano Zacarias Fluck, Marta Escorihuela

Baez, Antonio Jesus Esgueva Colmenarejo, Tomas Cortadellas Rosell, Martin Espinosa Bravo

Envejecimiento celular prematuro y cáncer de mama. Papel de la metaloproteasa ADAM17

Fundación Sandra Ibarra

Importe: 25.000 €

Marzo 2013 – Febrero 2014

HER2-induced cellular senescence in breast cancer progression and treatment

Breast Cancer Research Foundation

Importe: 240.000 dólares

Octubre 2012-Octubre 2013

Equipo investigador: Kim Pedersen, Josep Lluís Parra Palau, Beatriz Morancho, Aniello Cerrato.

Nuevas estrategias para tratar el cáncer de mama positivo para HER2

Asociación Española Contra el Cáncer

Importe: 1.200.000 euros

Septiembre 2012-Septiembre 2017

Equipo investigador: Kim Pedersen, Josep Lluís Parra Palau, Beatriz Morancho Armisen, Aniello Cerrato, Mariano

Z. Fluck Zacarías, Agueda Martínez Barriocanal, Pier Davide Angelini, Rocio Vicario, Antonio Luque Garcia, Marta

Escorihuela Baez, Cristina Ferrer Ramón, Javier Cortés Castán, Isabel Rubio Rodriguez, Ludmila Prudkin, Ana

Vivancos Prellezo, Vicente Peg.

Tratamiento de la hiperactivación de HER2 en Cáncer de mama

AVON Cosmetics Foundation


Mayo 2012-Mayo 2015

Equipo investigador: Josep Tabernero Caturla, Aleix Prat Aparicio, Isabel Rubio Rodriguez, Francesc Canals,

Josep Lluis Parra Palau, Kim Pedersen, Beatriz Morancho Armisen, Joan Josep Bech Serra, Ludmila Prudkin,

Vicente Peg, Cristina Bernadó Morales, Antonio Luque García, Cristina Ferrer Ramón

Functional characterization of novel factors mediating the oncogenic activity of HER2. Role in the progression of

breast cancer

12


Importe: 500.000 dolares


Equipo investigador: Kim Pedersen, Josep Lluís Parra Palau, Beatriz Morancho Armisen, Aniello Cerrato, Pier

Davide Angelini, Cristina Bernadó Morales, Cristina Ferrer Ramón, Marta Escorihuela, Antonio Luque García.

Research Collaboration Agreement (Glaxo Smith Kline)

Glaxo Smith Kline


Octubre 2009-Diciembre 2012

Equipo investigador: Kim Pedersen, Josep Lluís Parra Palau, Beatriz Morancho Armisen, Mariano Zacarías Fluck,

Pier Davide Angelini, Marta Escorihuela Baez

Novel factors and mechanisms mediating the oncogenic activity of HER2




Equipo investigador: Kim Pedersen, Josep Lluís Parra Palau, Beatriz Morancho Armisen, Pier Davide Angelini,

Cristina Bernadó Morales, Cristina Ferrer Ramón, Antonio Luque Garcia.

Desarrollo tecnológico de anticuerpos monoclonales con interés diagnóstico y/o terapéutico contra el receptor

HER2 y/o sus variantes truncadas

Genoma España


Mayo 2009-Diciembre 2011

Equipo investigador: Josep Lluís Parra Palau, Marta Escorihuela

Ajuts de Suport a la Recerca. Grup de Recerca Consolidat

Agencia de Gestió d'Ajuts Universitaris i de Recerca

Referencia: 2009SGR328


Enero 2009-Enero 2014

13

Equipo investigador: Francesc Canals Suris, Kim Pedersen, Cary Esselens, Jordi Malapeira Argilaga, Josep Lluis

Parra Palau, Beatriz Morancho Armisen, Matthew Paul Cuningham, Mariano Zacarias Fluck, Veronica Calvo Vidal,

Pier Davide Angelini, Cristina Bernadó Morales, Cristina Ferrer Ramón, Antonio García Luque, Sandra Paola

Mancilla, Marta Escorihuela Baez, Silvia Corvinos Mezcua, Nuria Colomé Calls, Joan Josep Bech Serra, Marta

Monge Azemar, Sandra Porta Martínes, Susana Muñiz Lopez.

Fragmentos Carboxilo Terminales (CTFs) en la progresión y tratamiento de cáncer de mama





Equipo investigador: Kim Pedersen, Cary Esselens, Jesús Garcia Castillo, Sirle Laos, Josep Lluís Parra Palau,

Jordi Malapeira Argilaga, Matthew Paul Cunningham, Pier Davide Angelini, Maria Ines Barreto Das Neves Lopes

Texeira, Sandra Paola Mancilla, Cristina Ferrer Ramón, Antonio Miguel Luque García.

Metastasis in breast tumors expressing 611-CTF of HER2: mechanisms and therapeutic strategies




Equipo investigador: Kim Pedersen, Josep Lluis Parra Palau, Sirle Laos, Mathew Paul Cunningham, Pier Davide

Angelini.

Referencia: RD06/0020/0022

Red Temática de Investigación Cooperativa

Instituto de Salud Carlos III (Subdirección General de REdes y Centros de Investigación Cooperativa)

Importe: 1.666.587 euros


Equipo investigador: Francesc Canals, Maria Belen Santiago Josefat, Kim Pedersen, Cary Esselens, Lluis Parra

Palau, Jordi Malapeira, Manel Garcia Medina, Matthew Paul Cuningham, Mariano Zacarias Fluck, Judit Anido

Folgueira, Pier Davide Angelini, Rocio Vicario, Cristina Bernadó, Cristina Ferrer Ramón, Antonio Miguel Luque

Garcia,

Identificación de mecanismos y factores involucrados en la sobreexpresión y tráfico intracelular de ADAM17

(TACE). Relevancia para el desarrollo de tumores de mama

Fundación Mutua Madrileña


14

Mayo 2007-Mayo 2010

Equipo investigador: Josep Baselga Torres, Francesc Canals, Cary Esselens, Jordi Malapeira, Ines Das Neves

Lopez Texeira, Cristina Ferrer Ramón, Joan Josep Bech Serra.

Identification of factors and mechanisms leading to metastasis in breast tumors expressing HER2 Carboxy

Terminal Fragments.




Equipo investigador: Kim Pedersen, Jesus García Castillo, Josep Lluis Parra Palau, Sirle Laos, Matthew Paul

Cunningham, Pier Davide Angelini.






Equipo investigador: Francesc Canals, Javier Cortés Castán, Belen Santiago Josefat, Kim Pedersen, Cary

Esselens, Soraya Ruiz Paz, Joan Josep Bech Serra, Maria Teresa Villanueva de la Torre, Rosaura Esteve Puig,

Nuria Colomé Calls, Meritxell Bellet Ezquerra, Judit Balmaña Gelpi, Cristina Ferrer Ramón, Marta Guzman Torres,

Silvia Corvinos Mezcua

Generación y caracterización de ratones transgénicos expresando Fragmentos C-Terminales del oncogén HER2

en glándulas mamaria

Ministerio de Educación y Ciencia

Referencia: SAF2005-03939



Equipo investigador: Belen Santiago Josefat, Sirle Laos, Jesus Garcia Castillo, Cary Esselens, Judit Anido

Folgueira, Pier Davide Angelini, Antonio Garcia Luque.

Identificació i caracterització dels mecanismes de tumorogènesis mediats pels fragments carboxiterminals de

HER2.

Fundació la Marató TV3

Referencia: 05010

15



Equipo investigador: Kim Pedersen, Cary Esselens, Judit Anido Folgueira

Red Temática (FIS Puente)



Importe : 196.350 euros


Equipo investigador: Francesc Canals Suris, Joan Seoane Suarez, Sonia Martínez Arca, Cristina Ferrer

Ramón, Rachel Darken, Maria del Carmen Plaza Calonge, Antoni Xavier Torres Collado, Raquel Batlle

Gomez, Alexandra Arias Piñeiro, Miguel Hurtado Kuttner, Silvia Corvinos Mezcua, Sandra Porta Martínez,

Marta González Martínez, Nuria Colomé Calls

Caracterización funcional y estructural de un nuevo producto del proto-oncogén HER2. Implicaciones terapéuticas

en cáncer de mama

Asociación Española Contra el Cáncer


Febrero 2005- Febrero 2008

Equipo investigador: Belen Santiago Josefat, Kim Pedersen, Judit Anido Folgueira, Antonio Garcia Luque,

Marta Guzman Torres, Maria Goretti Mallorqui Fernandez, Noemí Mallorqui Fernandez

Identificación del degradoma de la metaloproteasa desintegrina TACE: relevancia en el desarrollo de tumores de

mama

La Caixa

Referencia: BM05-208-00


Mayo 2005 – Mayo 2008

Equipo investigador: Jose Baselga Torres, Federico Gustavo Rojo Todo, Francesc Canals Suris, Belens

Santiago Josefat, Cary Esselens, Jordi Malapeira Argilaga,Teresa Villanueva de la Torre, Joan Josep Bech

Serra.

Signalling and Membrane Trafficking in Transformation and Differentiation

STREP

Comisión Europea

16

Referencia: FP6-503228



Equipo investigador: Sonia Martinez Arca, Cary Esselens, Joan Josep Bech Serra, Pier Davide Angelini,

Rosaura Esteve Puig, Miguel Hurtado Kutner.

Genomica del Cáncer. Genotipado de tumores

Instituto de Salud Carlos III (Subdirección General de REdes y Centros de Investigación Cooperativa)

Referencia: C03/10

Importe : 1.002.319 euros


Equipo investigador: Nuria Colomé Calls, Cristina Ferrer Ramón, Silvia Corvinos Mezcua, Francesc Canals

Surís, Sandra Porta Martínez, Javier Hernández Losa, Marta González Martínez, Joan Seoane Suárez,

Rachel Darken, Raquel Batlle Gomez, Alexandra Arias Piñeiro,

Juan Carlos Rodriguez-Manzaneque Escribano, Maria del Carmen Plaza Calonge, Antoni Xavier Torres

Collado, Sonia Martínez Arca, Miguel Hurtado Kuttner, Rossana Paciucci Barzanti, Anna Santamaría

Margalef, Sandra Vila Muga, Miguel Abal Posada, Francina Munell Casadesus, Tomás Pinos Figueras,

Antoni Huratdo Rodriguez, Alba Segovia Corrales, Simó Schwartz Navarro, Manel Armengol Carrasco, Eloi

Espín Basany, Hafid Alazzouzi, Laura García Latorre, Jesus Planaguma Valls, Marta Monge Azemar, Javier

Cortés Castán, Joaquín Bellmunt Molins, Juan Carulla Torrent, Josep Tabernero Caturla, Enriqueta Felip

Font, Marta Guzman Torres, Serena Di Cosimo, Santiago Ramon y Cajal Agueras, Matilde Esther Lleonart

Pajarín, Federico Gustavo Rojo Todo, Carmela Iglesias Felip, Miriam Cuatrecasas Freixas, Maria Díaz

Fuertes






Acción Especial EMBO

Ministerio de Ciencia y Tecnología.

Referencia: 2001-5069-E

45.000 euros

Enero 2003- Diciembre 2003

17

Papel del shedding de los ligandos de receptores HER en el desarrollo y progresión tumoral




Caraterización e identificación de componentes de la maquinaria de transporte a la superficie celular de receptores

de glutamato NMDA

Fundación La Marató de TV3

Referencia: 01810

101.198,42 euros


Shedding of pro-Transforming Growth Factor-alpha role of metalloprotease-disintegrins and pro-protein

convertases

EMBO Young Investigator Programme.

Referencia: 450



Identificación y caracterización de la maquinaria de transporte de proTGF-alpha a la superficie celular

Comisión Interministerial de Ciencia Y Tecnología (CICYT)


Importe: 162.624 euros (27.104.000 pesetas)


Regulación de las Adamalisinas y la vía ubiquitina-proteasoma en el procesamiento proteolítico de la bAPP

Fundación la Caixa

Referencia: 99/0020-1


1998-2001

Papel de las Adamalisinas en la generación del péptido Ab

18

Fundación La Marató de TV3

Referencia: 036/97


1998-2001

Identificación y caraterización de la maquinaria de corte activado de factores de crecimiento de transmembrana

Comisión Interministerial de Ciencia Y Tecnología (CICYT)



1997-2000

curriculum vitae joaquín v. arribas lópez (fecha...

Documents